AviadoBio’s Post

Good opportunity

🎉 Exciting News from PepGen! 🎉 PepGen has announced positive data from the low-dose cohort of their PGN-EDO51 in the ongoing Phase 2 CONNECT1-EDO51 clinical trial for Duchenne Muscular Dystrophy (DMD)! 🔬 Highlights 🔬 🧬Well Tolerated: PGN-EDO51 at 5 mg/kg was well tolerated, with all patients continuing to the long-term extension phase. 🧬Exon Skipping: Achieved mean exon skipping levels of 2.15% after just 3 months. 🧬Dystrophin Production: A significant increase in muscle-adjusted dystrophin levels, with a mean level of 1.49%, a 0.70% rise from baseline. 🧬Safety: Demonstrated a favorable safety profile, supporting ongoing evaluations. 🧬Their Enhanced Delivery Oligonucleotide (EDO) technology is proving to be a game-changer, delivering higher levels of oligonucleotide to nuclei, indicating stronger potency at lower doses. James McArthur, CEO, stated, "We are encouraged by the early data, which shows PGN-EDO51 produced higher levels of exon skipped transcript at lower doses and in a shorter time period compared to other therapies." #Biotech #DMD #ClinicalTrials #Innovation #PepGen #Healthcare #MedicalResearch #Pharma

If you're looking for rapid maturation times and functional iPSC-derived cells, let's have a conversation. In vitro drug discovery is fast-paced; speedier results mean quicker iterations, nimble operations and fewer steps to success, all while saving money. That's why we've developed our axoCells range for fast maturation to robust, functional end point cells. Take a look at the graphic to see the maturation times for our axoCells™ neurons, neuroinflammatory cells and cardiomyocytes. Explore our axoCells Catalog to see the data, applications and product information for our leading axoCells range: https://lnkd.in/epUnnZWt #iPSCs #StemCells #biopharma

Time is money in drug discovery. So key question is: “How long until my iPSC’s are assay ready and showing a functional response/signal ?” See answers below!! #cellculture #microfluidics #organoids #organonchip #drugdiscovery #drugdevelopment #biotech #pharma #neuroscience #PNS #mea

#ENVBUpdate – Enveric Biosciences, Inc., announced the selection of EB-003 as its lead drug candidate from the Company’s next-generation EVM301 Series. EB-003 was selected based on data analyses suggesting the molecule's potential to be a first-in-class approach to addressing difficult-to-treat mental health disorders by promoting neuroplasticity without inducing hallucinations. Enveric plans to initiate preclinical development of EB-003 in early 2024 in preparation for an IND application for a first-in-human clinical trial. To learn more about EB-003, click here: https://lnkd.in/eUy8PYvK #ENVB #MentalHealth #Psilocybin #Biotechnology

📅 Save the Date: September 7th! Join us for the second in a series of Oncofactory’s webinars showcasing new ERBC's innovative technology platform for the evaluation of novel anticancer agents. Our platform is based on an #avian embryo patient-derived xenograft (AVI-PDX) model developed and patented by Oncofactory, an ERBC Group company. This interactive webinar will answer your burning questions about the real-world application of the AVI-PDX model. With Valerie Castellani Lincontang, PhD, Founder and Chief Scientific Officer of Oncofactory, and guest speaker Karine Aguera, Chief Development Officer at StromaCare, previously R&D Project leader at ERYTECH Pharma. 👉 Register here: https://lnkd.in/e9rJWMFA Not available? Register anyway and get access to the session replay. Also, mark your calendars for our third webinar on September 28, 2023, where we will delve into clinical case studies. (Link to register: https://lnkd.in/eWn5hBEF) See you soon. For more information on the Oncofactory platform overview and to view the Webinar 1 replay, click here: https://lnkd.in/eYhXF2Ns #Lifescience #testing #efficacy #research #PDXmodel #invivomodels #CRO #drugdevelopment #ethicalpractice #NAM #nonclinical #biotech #TNBC

Publication Alert 📢 Topic : INTOLERANCE OF UNCERTAINTY AND MULTIDIMENSIONAL PERFECTIONISM IN INDIVIDUALS WITH OCD: THE MEDIATING ROLE OF SELF-COMPASSION. Journal: The Journal of Population Therapeutics and Clinical Pharmacology- classified under HEC X category Link: https://lnkd.in/dcbrVQpQ

📌 CardioReGenix project | March 2024 Progress Meeting   ▶ The #EUfunded CardioReGenix project focuses on technological innovations for the treatment of #heartfailure and #myocardialischemia, and its partners held last week a two-day progress meeting to share the most recent updates on the project.   ▶ #CardioReGenix project partners are top-scientists in the area of #cardiovascular #research & #treatment, and #genetherapies. Our expert Laura Mendieta attended the meeting to update on ASPHALION’s #Regulatory developments. ASPHALION is currently participating in the drafting of the #IMPDs and #IB documents for a future #ClinicalTrial to evaluate a #GeneTherapy #InvestigationalMedicinalProduct for the treatment of #coronary #HeartDisease.   📧 For further information, you can contact us at: info@asphalion.com #CardiovascularDisease #Europe #HORIZON #RA #RegulatoryAffairs #CTIS #WeAreAsphalion #WeCare #KnowledgeFromExperience  https://bit.ly/3vbfqKr

One week until the Maryland Tech Council Bioinnovation Conference. If you've heard of Organ on Chip, or even if you haven't, make sure to stop by our booth #23 to learn how Emulate, Inc. can enhance your drug development pipeline with human relevant preclinical data on your lead candidates. Our human organ models include liver, kidney & intestine among others, with workflows for #CGT, #ICR and general toxicity. Find the no, faster with #organonchip

Did you miss last week’s webinar: Safety Considerations for the Development of Antibody-Drug Conjugates? No problem! The recording and slides are now available: https://hubs.ly/Q0284-wS0 Since both #antibody and #smallmolecule drug components can contribute to #druginteractions, ADCs should be considered from a safety perspective. This webinar examines #ADCs that are currently approved and in the clinic, outline experimental strategies for identification of drug interaction potential, and more!